Neurocrine Biosciences, Inc’s filing revealed that its Chief Executive Officer Gano Kyle unloaded Company’s shares for reported $9.2 million on Jan 15 ’25. In the deal valued at $141.50 per share,65,000 shares were sold. As a result of this transaction, Gano Kyle now holds 135,392 shares worth roughly $19.75 million.
Then, KYLE W GANO bought 65,000 shares, generating $9,068,150 in total proceeds.
Before that, Delaet Ingrid sold 272 shares. Neurocrine Biosciences, Inc shares valued at $37,563 were divested by the Chief Regulatory Officer at a price of $138.10 per share. As a result of the transaction, Delaet Ingrid now holds 2,507 shares, worth roughly $0.37 million.
A number of analysts have revised their coverage, including Piper Sandler’s analysts, who increased its forecast for the stock in late August from “a Neutral” to “an Overweight”. Wells Fargo also remained covering NBIX and has increased its forecast on April 24, 2024 with a “an Overweight” recommendation from previously “an Equal weight” rating.
Price Performance Review of NBIX
On Tuesday, Neurocrine Biosciences, Inc [NASDAQ:NBIX] saw its stock jump 1.83% to $145.88. Over the last five days, the stock has gained 1.99%. Neurocrine Biosciences, Inc shares have risen nearly 6.87% since the year began. Nevertheless, the stocks have risen 6.68% over the past one year. While a 52-week high of $157.98 was reached on 01/21/25, a 52-week low of $110.95 was recorded on 01/06/25. SMA at 50 days reached $131.49, while 200 days put it at $132.99.
Levels Of Support And Resistance For NBIX Stock
The 24-hour chart illustrates a support level at 144.15, which if violated will result in even more drops to 142.42. On the upside, there is a resistance level at 146.94. A further resistance level may holdings at 148.00. The Relative Strength Index (RSI) on the 14-day chart is 70.01, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.71, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 3.80%. Stochastics %K at 86.93% indicates the stock is a selling.
How much short interest is there in Neurocrine Biosciences, Inc?
A steep rise in short interest was recorded in Neurocrine Biosciences, Inc stocks on 2024-12-31, dropping by -0.56 million shares to a total of 3.35 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 3.91 million shares. There was a decline of -16.7%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $136 price target.
